ALNY / Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease

Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration more_horizontal

We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is more_horizontal

Despite a positive panel recommendation, the FDA rejected the Alnylam Pharmaceuticals, Inc. application to market Onpattro for ATTR-CM, citing a lack more_horizontal

Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL more_horizontal

Tesla (TSLA) shares are in focus as China-made EV demand drops by 10%, affecting Model 3 and Y sales. Tesla's delivery and production data declined fr more_horizontal

Drugmaker Alnylam wanted to expand approval of its drug Onpattro, but the Food and Drug Administration rejected the application even after an outside more_horizontal

The U.S. Food and Drug Administration has declined to approve the expanded use of Alnylam Pharmaceuticals' drug to treat a rare and fatal heart diseas more_horizontal

Alnylam Pharmaceuticals Inc. ALNY, -1.00% said Monday it would no longer pursue its supplemental new drug application (sNDA) for patisiran as a treatm more_horizontal